References
- Yang H, Kim SK, Kim M et al. Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction. J. Clin. Invest.115, 379–387 (2005).
- Reeves PM, Bommarius B, Lebeis S et al. Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases. Nat. Med.11, 731–739 (2005).
- Koon HB, Bubley GJ, Pantanowitz L et al. Imatinib-induced regression of AIDS-related Kaposi's sarcoma. J. Clin. Oncol.23, 982–989 (2005).
- Kim M, Yang H, Kim SK et al. Biochemical and functional analysis of smallpox growth factor (SPGF) and anti-SPGF monoclonal antibodies. J. Biol. Chem.279, 25838–25848 (2004).
- Baselga J: Targeting the epidermal growth factor receptor with tyrosine kinase inhibitors: small molecules, big hopes. J. Clin. Oncol.20, 2217–2219 (2002).
- Schang LM: Cyclin-dependent kinases as cellular targets for antiviral drugs. J. Antimicrob. Chemother.50, 779–792 (2002).
- Schang LM: Herpes simplex viruses in antiviral drug discovery. Curr. Pharm. Des.12, 1357–1370 (2006).
- Moses AV, Jarvis MA, Raggo C et al. Kaposi’s sarcoma-associated herpesvirus-induced upregulation of the c-kit proto-oncogene, as identified by gene expression profiling, is essential for the transformation of endothelial cells. J. Virol.76, 8383–8399 (2002).
- Sturzl M, Roth WK, Brockmeyer NH, Zietz C, Speiser B, Hofschneider PH: Expression of platelet-derived growth factor and its receptor in AIDS-related Kaposi sarcoma in vivo suggests paracrine and autocrine mechanisms of tumor maintenance. Proc. Natl Acad. Sci. USA89, 7046–7050 (1992).
- Demetri GD, von Mehren M, Blanke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med.347, 472–480 (2002).
- Rubin BP, Schuetze SM, Eary JF et al. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J. Clin. Oncol.20, 3586–3591 (2002).
- Cools J, DeAngelo DJ, Gotlib J et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med.348, 1201–1214 (2003).